| value |
{"aggregator_url":"https://news.google {"aggregator_url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNTUJ4MEZmWDVKaWNsam4tMWxUejBSSXpVRUdrTWR2RmRfeW93UUdMT1k5NlA5TThpRHBuZ3JfV1NtMXQxb2drT0R1cEZHNXRaV2JCSVItR3BiZFN1OHVUMHNubGpqdzlySVlEbWdkWHJCOThiLW9yVktob3pUZWE0aDFpaUNqM28?oc=5","as_of":"2026-04-10T17:21:18.772571+00:00","canonical_url":"https://www.gstatic.com/_/mss/boq-dots/_/ss/k=boq-dots.DotsSplashUi_desktop_ms.OYgPNdDf9Nc.L.X.O/am=GAIFAAAADpgFDCgAAQ/d=1/ed=1/rs=ALs0n2OYSmDAUDetpsORI83j3dpsv55GJQ/m=syndicationarticleview,_b,_tp","enrichment":{"aggregator_url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNTUJ4MEZmWDVKaWNsam4tMWxUejBSSXpVRUdrTWR2RmRfeW93UUdMT1k5NlA5TThpRHBuZ3JfV1NtMXQxb2drT0R1cEZHNXRaV2JCSVItR3BiZFN1OHVUMHNubGpqdzlySVlEbWdkWHJCOThiLW9yVktob3pUZWE0aDFpaUNqM28?oc=5","article_chars":0,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_0bf3410fc11aca07","canonical_host":"gstatic.com","canonical_is_aggregator":true,"canonical_url":"https://www.gstatic.com/_/mss/boq-dots/_/ss/k=boq-dots.DotsSplashUi_desktop_ms.OYgPNdDf9Nc.L.X.O/am=GAIFAAAADpgFDCgAAQ/d=1/ed=1/rs=ALs0n2OYSmDAUDetpsORI83j3dpsv55GJQ/m=syndicationarticleview,_b,_tp","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-11T20:08:03.586528+00:00","extraction_method":"none","fetched_description":"","fetched_title":"","final_url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNTUJ4MEZmWDVKaWNsam4tMWxUejBSSXpVRUdrTWR2RmRfeW93UUdMT1k5NlA5TThpRHBuZ3JfV1NtMXQxb2drT0R1cEZHNXRaV2JCSVItR3BiZFN1OHVUMHNubGpqdzlySVlEbWdkWHJCOThiLW9yVktob3pUZWE0aDFpaUNqM28?oc=5&hl=en-US&gl=US&ceid=US:en","html_truncated":true,"paywall_likely":false,"publisher_domain":"gstatic.com","publisher_resolution":"canonical_aggregator_unresolved","requested_url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNTUJ4MEZmWDVKaWNsam4tMWxUejBSSXpVRUdrTWR2RmRfeW93UUdMT1k5NlA5TThpRHBuZ3JfV1NtMXQxb2drT0R1cEZHNXRaV2JCSVItR3BiZFN1OHVUMHNubGpqdzlySVlEbWdkWHJCOThiLW9yVktob3pUZWE0aDFpaUNqM28?oc=5","source_event_id":"evt_0a8c4dc3ae7a","source_quality":"empty","status_code":200,"version":"signal_enrichment_v2"},"fp":"5930927509d41671","kind":"ipo_calendar","published_at":"2026-04-10T16:23:06+00:00","publisher_domain":"gstatic.com","signal_understanding":{"analysis_basis":"headline_and_summary","claim_confidence":0.6,"dates_mentioned":[],"entities":[{"asset_class":"equity","name":"Avalyn","relevance":"high","symbol":"AVLN","type":"company"}],"event_type":"listing","information_gaps":["No article body text is provided, so IPO timing, offering size, pricing, underwriters, exchange, and regulatory filings are unknown.","No confirmation of whether the IPO has been filed, approved, or is at a specific stage is provided.","No financial metrics or business details beyond 'inhaled drug developer' are included."],"key_facts":["Avalyn is described as an inhaled drug developer.","Avalyn is seeking a U.S. IPO.","The IPO/ticker is shown as AVLN:Pending."],"numeric_claims":[],"primary_claim":"Avalyn, an inhaled drug developer, is seeking a U.S. IPO.","relevance_score":0.55,"sentiment":"neutral","source_quality":"unknown","summary":"The signal reports that inhaled drug developer Avalyn is seeking a U.S. IPO. The ticker is listed as pending (AVLN:Pending), but no further IPO details are provided in the available text.","topics":["IPO","U.S. listing","inhaled drugs","biopharma"]},"source":"Seeking Alpha","source_domain":"gstatic.com","summary":"Inhaled drug developer Avalyn seeks U.S. IPO (AVLN:Pending) Seeking Alpha","tickers":[],"title":"Inhaled drug developer Avalyn seeks U.S. IPO (AVLN:Pending) - Seeking Alpha","url":"https://www.gstatic.com/_/mss/boq-dots/_/ss/k=boq-dots.DotsSplashUi_desktop_ms.OYgPNdDf9Nc.L.X.O/am=GAIFAAAADpgFDCgAAQ/d=1/ed=1/rs=ALs0n2OYSmDAUDetpsORI83j3dpsv55GJQ/m=syndicationarticleview,_b,_tp"}... |